{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:00:52Z","timestamp":1791856852376,"version":"4.3.4"},"reference-count":56,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2018,9,1]]},"DOI":"10.1001\/jamaneurol.2018.1346","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T16:31:17Z","timestamp":1528734677000},"page":"1062","source":"Crossref","is-referenced-by-count":137,"title":["Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort"],"prefix":"10.1001","volume":"75","author":[{"given":"Arno","family":"de Wilde","sequence":"first","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Epidemiology & Biostatistics, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje","family":"Pelkmans","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"Bouwman","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurre","family":"Verwer","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Groot","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke M.","family":"van Buchem","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Zwan","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Kunneman","sequence":"additional","affiliation":[{"name":"Department of Medical Psychology, Amsterdam Neuroscience, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen M. A.","family":"Smets","sequence":"additional","affiliation":[{"name":"Department of Medical Psychology, Amsterdam Neuroscience, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Institutes of Neurology and Healthcare Engineering, University College London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan A.","family":"Lammertsma","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stephens","sequence":"additional","affiliation":[{"name":"Piramal Imaging GmbH, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Lier","sequence":"additional","affiliation":[{"name":"BV Cyclotron, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert Jan","family":"Biessels","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N.","family":"van Berckel","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"},{"name":"Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[{"name":"Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5054","key":"noi180034r1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer\u2019s disease: the amyloid cascade hypothesis.","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"issue":"5580","key":"noi180034r2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics.","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"issue":"2","key":"noi180034r3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers.","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi180034r4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B.","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol"},{"issue":"3","key":"noi180034r5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi180034r6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"6","key":"noi180034r7","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria.","volume":"13","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"issue":"10043","key":"noi180034r8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease.","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"noi180034r9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u00df plaques: a prospective cohort study.","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi180034r10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jalz.2015.05.018","article-title":"[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer\u2019s disease: specific detection of advanced phases of amyloid-\u00df pathology.","volume":"11","author":"Thal","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"8","key":"noi180034r11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: phase 3 study.","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi180034r12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.dadm.2014.11.004","article-title":"A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer\u2019s disease.","volume":"1","author":"Yeo","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"noi180034r13","doi-asserted-by":"publisher","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association.","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"11","key":"noi180034r14","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","article-title":"Clinical use and utility of amyloid imaging.","volume":"58","author":"Barthel","year":"2017","journal-title":"J Nucl Med"},{"key":"noi180034r15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","article-title":"Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase development framework.","volume":"52","author":"Chiotis","year":"2017","journal-title":"Neurobiol Aging"},{"key":"noi180034r16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.dadm.2017.01.003","article-title":"Alzheimer\u2019s biomarkers in daily practice (ABIDE) project: Rationale and design.","volume":"6","author":"de Wilde","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"noi180034r17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12883-014-0254-4","article-title":"The Dutch Parelsnoer Institute\u2014neurodegenerative diseases; methods, design and baseline results.","volume":"14","author":"Aalten","year":"2014","journal-title":"BMC Neurol"},{"issue":"1","key":"noi180034r18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/JAD-132306","article-title":"Optimizing patient care and research: the Amsterdam Dementia Cohort.","volume":"41","author":"van der Flier","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"noi180034r19","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants.","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"noi180034r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop.","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"key":"noi180034r21","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia.","volume":"54","author":"Boeve","year":"2003","journal-title":"Ann Neurol"},{"issue":"2","key":"noi180034r22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/WNL.43.2.250","article-title":"Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.","volume":"43","author":"Rom\u00e1n","year":"1993","journal-title":"Neurology"},{"issue":"6","key":"noi180034r23","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1212\/WNL.51.6.1546","article-title":"Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.","volume":"51","author":"Neary","year":"1998","journal-title":"Neurology"},{"issue":"12","key":"noi180034r24","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"noi180034r26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00006199-198109000-00002","article-title":"The measurement of uncertainty in illness.","volume":"30","author":"Mishel","year":"1981","journal-title":"Nurs Res"},{"issue":"8","key":"noi180034r28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers.","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol"},{"issue":"1","key":"noi180034r29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/13554794.2017.1290806","article-title":"Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.","volume":"23","author":"Weidman","year":"2017","journal-title":"Neurocase"},{"issue":"1","key":"noi180034r30","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000356273","article-title":"Re-evaluation of clinical dementia diagnoses with Pittsburgh compound B positron emission tomography.","volume":"3","author":"Degerman Gunnarsson","year":"2013","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"1","key":"noi180034r31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1159\/000345783","article-title":"Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis.","volume":"2","author":"Frederiksen","year":"2012","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"2","key":"noi180034r32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00115-016-0249-z","article-title":"[Amyloid positron-emission-tomography with [18?F]-florbetaben in the diagnostic workup of dementia patients].","volume":"88","author":"Sch\u00f6necker","year":"2017","journal-title":"Nervenarzt"},{"issue":"4","key":"noi180034r33","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3233\/JAD-151180","article-title":"Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers.","volume":"52","author":"Bensa\u00efdane","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"noi180034r34","first-page":"561","article-title":"Impact of florbetaben PET imaging on diagnosis and management of patients with suspected Alzheimer\u2019s disease eligible for CSF analysis in France.","volume":"58","author":"Ceccaldi","year":"2017","journal-title":"J Nucl Med"},{"key":"noi180034r35","first-page":"S624","article-title":"First experience of 100 clinical F-18 florbetapir (Amyvid) PET\/CT scans in the investigation of cognitive impairment: imaging characteristics, inter-observer agreement, confidence of read and clinical outcomes.","volume":"43","author":"Khan","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"noi180034r36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","article-title":"Diagnostic impact of [18F]flutemetamol PET in early-onset dementia.","volume":"9","author":"Zwan","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi180034r37","first-page":"327","article-title":"Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer\u2019s disease and other dementias in a regional memory clinic in Hong Kong.","volume":"22","author":"Shea","year":"2016","journal-title":"Hong Kong Med J"},{"issue":"3","key":"noi180034r38","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1212\/WNL.0000000000000032","article-title":"Practical utility of amyloid and FDG-PET in an academic dementia center.","volume":"82","author":"S\u00e1nchez-Juan","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"noi180034r39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","article-title":"Impact of molecular imaging on the diagnostic process in a memory clinic.","volume":"9","author":"Ossenkoppele","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi180034r40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1326-9-10","article-title":"A consecutive case series experience with [18?F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition.","volume":"9","author":"Mitsis","year":"2014","journal-title":"Mol Neurodegener"},{"issue":"1-2","key":"noi180034r41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000441139","article-title":"Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: impact of appropriate use criteria.","volume":"41","author":"Grundman","year":"2016","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"noi180034r42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","article-title":"Assessment of the incremental diagnostic value of florbetapir f 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET With [18F]-florbetapir (INDIA-FBP) study.","volume":"73","author":"Boccardi","year":"2016","journal-title":"JAMA Neurol"},{"key":"noi180034r43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.dadm.2016.12.001","article-title":"Critical review of the appropriate use criteria for amyloid imaging: effect on diagnosis and patient care.","volume":"5","author":"Apostolova","year":"2016","journal-title":"Alzheimers Dement (Amst)"},{"issue":"3-4","key":"noi180034r44","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000478007","article-title":"Effectiveness of florbetapir PET imaging in changing patient management.","volume":"44","author":"Pontecorvo","year":"2017","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"4","key":"noi180034r45","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3233\/JAD-160302","article-title":"Diagnosing dementia in the clinical setting: can amyloid pet provide additional value over cerebrospinal fluid?","volume":"54","author":"Weston","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"noi180034r46","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jalz.2017.01.022","article-title":"Safety of disclosing amyloid status in cognitively normal older adults.","volume":"13","author":"Burns","year":"2017","journal-title":"Alzheimers Dement"},{"key":"noi180034r47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.nicl.2013.02.006","article-title":"Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer\u2019s disease.","volume":"2","author":"Ch\u00e9telat","year":"2013","journal-title":"Neuroimage Clin"},{"issue":"1","key":"noi180034r48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/nmt.12.75","article-title":"Should we disclose amyloid imaging results to cognitively normal individuals?","volume":"3","author":"Grill","year":"2013","journal-title":"Neurodegener Dis Manag"},{"issue":"3","key":"noi180034r49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2217\/nmt.13.25","article-title":"Amyloid imaging, risk disclosure and Alzheimer\u2019s disease: ethical and practical issues.","volume":"3","author":"Roberts","year":"2013","journal-title":"Neurodegener Dis Manag"},{"issue":"3","key":"noi180034r50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.dadm.2015.06.006","article-title":"Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.","volume":"1","author":"Witte","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"noi180034r51","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jalz.2015.09.005","article-title":"Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.","volume":"12","author":"Lim","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"10","key":"noi180034r52","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study.","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol"},{"issue":"5","key":"noi180034r53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jalz.2012.08.004","article-title":"Cerebrospinal fluid A\u00df42 is the best predictor of clinical progression in patients with subjective complaints.","volume":"9","author":"van Harten","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"22","key":"noi180034r54","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons.","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"228","key":"noi180034r55","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"noi180034r56","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jalz.2012.09.014","article-title":"Disclosure of amyloid imaging results to research participants: has the time come?","volume":"9","author":"Lingler","year":"2013","journal-title":"Alzheimers Dement"},{"key":"noi180034r25","volume-title":"Manual for the State-Trait Anxiety Inventory","author":"Spielberger","year":"1983"},{"key":"noi180034r27","volume-title":"Intelligentie en Leeftijd: Onderzoek Bij Nederlanders Van Twaalf Tot Zevenenzeventig Jaar [Intelligence and Age: Study with Dutch People Aged 12 to 77]","author":"Verhage","year":"1964"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2683867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T09:57:05Z","timestamp":1604397425000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2018.1346"}},"subtitle":["The ABIDE Project"],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2018.1346","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}